VA Expansion Neurolief has secured a Department of Veterans Affairs contract to provide Proliv(R) Rx for adults with major depressive disorder and Relivion(R) MG for acute migraine, presenting a strategic entry point into large federal healthcare networks and a potential path to scale within veteran populations and related payor channels.

FDA Approved Growth With FDA approval for Proliv Rx and a recent financing round to expand access, Neurolief is positioned to accelerate physician adoption and payer coverage initiatives, signaling readiness for expanded clinical trials, hospital partnerships, and integrated delivery networks.

Clinical Leadership Recent hires of a Chief Medical Officer and a Chief Commercial Officer underscore a focused strategy on clinical validation and commercial scale, suggesting opportunities to collaborate on clinical guidelines, KOL engagements, and hospital/systemwide deployment.

Integrated Care Fit Neurolief’s noninvasive brain stimulation targets depression and migraine pathways, aligning with trends toward at-home physician-directed therapies and scalable neuromodulation within large health systems, VA networks, and payor-supported care models.

Funding Momentum Continued investor backing alongside regulatory approvals indicates momentum for partnerships with payors, distributors, and health systems seeking cost-effective, scalable neuromodulation solutions for MDD and migraine across diverse patient populations.